bluuebunny/crossref_metadata_2025 huggingface dataset:
P925Risk adjusted comparison of in-hospital outcomes of transapical transcatheter and surgical aortic valve replacement
Authors: Stachon P , Kaier K K , Heidt T H , Zehender M Z , Bode C B , Von Zur Muehlen C M
Published: October 2019

Background

Transfemoral transcatheter aortic valve replacement (TF-TAVR) is the standard therapy for patients with severe aortic valve stenosis at high operative risk. If the transfemoral access is not possible, a transapical access is an alternative. However, it is known from randomized trials and large registries that outcomes after transapical TAVR (TA-TAVR) are inferior to TF-TAVR.

Purpose

We compared in-hospital outcomes of patients undergoing TA-TAVR or SAVR in a nationwide data-set, in order to identify patients' groups, who benefit from SAVR or TA-TAVR.

Methods

We identified all 13,151 isolated SAVR and 4,625 TA-TAVR performed in Germany 2014 and 2015 on the basis of ICD- and OPS codes. In order to compare outcomes, we adjusted for risk factors using a covariate adjusted analysis.

Results

Patients undergoing TA-TAVR were older (68 vs. 80 years), had more co-morbidities, and accordingly an increased logistic EuroSCORE (LogES 5.3 vs 16.7%). However, stroke, acute kidney injuries, relevant bleedings, and prolonged mechanical ventilation occurred less frequently in patients undergoing TA-TAVR (OR TA-TAVR vs SAVR: stroke 0.66, p=0.017; acute kidney injury 0.72, p=0.002; relevant bleeding: 0.38, p<0.001; prolonged mechanical ventilation >48h: 0.5, p≤0.001). The risk for a new permanent pacemaker was higher after TA-TAVR (OR 2.44, p≤0.001). Without adjustment in-hospital mortality was higher after TA-TAVR (2.0% vs. 5.9%). After covariate adjustment, the difference disappeared (OR TA-TAVR vs. SAVR 1.2, p=0.136). In order to identify subgroups, which may benefit from TA-TAVR or SAVR, we compared mortality in different subgroups after risk adjustment. Patients under 75 years (OR TA-TAVR vs. SAVR: 1.86, p=0.01) and female (OR 1.48, p=0.043) patients had a lower risk for in-hospital mortality after SAVR. In all other groups (age 75–79, 80–84, >85, log. EuroScore <4, 4–9,>9, NYHA III/IV, previous CABG, COPD, pulmonary hypertension, chronic renal failure, Diabetes) none of both treatment strategies was superior.

Conclusion

TA-TAVR is with regard to in-hospital mortality not superior to SAVR in clinical practice. Younger patients under 75 years and female patients benefit from SAVR. However, complications such as bleeding, stroke, or prolonged ventilation were less frequently in patients undergoing TA-TAVR.
P932Structural changes in left ventricle after transcatheter aortic valve implantation
Authors: Ito N , Zen K , Kadoya Y , Kuwabara K , Yamano M , Yamano T , Nakamura T , Numata S , Sakai O , Oka K , Yaku H , Matoba S
Published: October 2019

Background

Transcatheter aortic valve implantation (TAVI) has improved prognosis and quality of life of patients with severe aortic stenosis (AS) who had been considered inoperable or at high risk for surgical aortic valve replacement reflecting their age, frailty, and comorbidities. However, less is known about changes in cardiac geometry after TAVI procedure, and predictors of them.

Purpose

To clarify changes in cardiac geometry after TAVI, and their predictors.

Methods

We retrospectively analyzed patients with severe AS who underwent TAVI in our institute between May 2016 and June 2018. Of the 117 consecutive patients enrolled to this study, 12 patients died before six-month follow up, and finally 88 patients received follow up exams including echocardiography at six months after TAVI procedure.

Results

The analysis of echocardiographic data at the baseline and the six-month follow up of the 88 patients (age 86.2±4.0 years, male 19.3%, STS-PROM 6.76±3.28%, peak aortic jet velocity 4.67±0.75m/s) revealed that left ventricular end-diastolic volume index (LVEDVi) (from 80.1±20.9ml/m2to 74.2±15.9ml/m2, p=0.011), and left ventricular mass index (LVMi) (from 116.0±32.7g/m2to 93.6±25.6g/m2, p<0.001) had improved in six months after TAVI procedure. The difference of LVEDVi (ΔLVEDVi: six-month LVEDVi–baseline LVEDVi) and the difference of LVMi (ΔLVMi: six-month LVMi – baseline LVMi) were significantly higher in the patients with chronic atrial fibrillation compared to the rest (ΔLVEDVi: +7.7±8.7ml/m2 vs −7.2±18.1ml/m2, p=0.024; ΔLVMi: +7.1±11.5g/m2 vs −25.3±33.5g/m2, p=0.008). In echocardiographic data, ΔLVEDVi and ΔLVMi both had positive correlation between baseline E/e' ratio (ΔLVEDVi: r=0.224, p=0.048; ΔLVMi: r=0.240, p=0.034), and negative correlation between baseline LVEDVi (ΔLVEDVi: r=−0.674, p<0.001; ΔLVMi: r=−0.312, p=0.003), LVMi (ΔLVEDVi: r=−0.422, p<0.001; ΔLVMi: r=−0.699, p<0.001), peak aortic jet velocity (ΔLVEDVi: r=−0.257, p=0.016; ΔLVMi: r=−0.376, p<0.001), and mean transaortic pressure gradient (ΔLVEDVi: r=−0.269, p=0.011; ΔLVMi: r=−0.403, p<0.001).

Conclusion

TAVI resulted in reverse remodeling and regression of hypertrophy in left ventricle. And these improvement were grater in patients with more advanced left ventricular remodeling and hypertrophy, and higher severity of AS at the baseline, however, less in patients with chronic atrial fibrillation and worse diastolic dysfunction.
P934Temporal trends in risk of atrial fibrillation and stroke in patients with peripheral artery disease between 1997 to 2015
Authors: Kamil S , Sehested T S G , Houlind K , Flensted Lassen J , Gislason G , Dominguez H M
Published: October 2019

Objectives

The risk of atrial fibrillation (AF) and stroke in patients with peripheral artery disease (PAD) is an important and inadequately addressed issue. Our aim was to examine temporal trends in the incidence of AF and stroke in patients with PAD.

Methods

Danish nationwide registers were used to identify all patients aged ≥18 years, with first-time diagnosis of PAD between 1997 and 2015. Age-standardized incidence rates per 1.000 person-years were calculated to estimate trends of AF and stroke. Risk of AF and stroke was furthermore estimated by 1-year cumulative-incidence divided into four year-groups.

Results

A total of 121.211 patients with first-time diagnosis of PAD were included. The 1-year cumulative-incidence of AF in patients with PAD were 1.97% for year 1997–2000, 2.63% for year 2001–2005, 2.66% for year 2006–2010, and 2.78% for year 2011–2015, respectively. The 1-year cumulative-incidence of stroke in patients with PAD were 2.71%, 2.71%, 1.95%, and 1.81%, for the 1997–2000, 2001–2005, 2006–2010, and 2011–2015 year-groups respectively. Likewise, the age-standardized incidence rates showed increasing trends of AF during the study period whereas trends of stroke demonstrated a decline (Figure 1). All age-standardized trends were statistically significant (p<0.05).

During the course of study i.e., between 1997 and 2015, the initiation of cholesterol-lowering agents, clopidogrel, and oral anticoagulants increased markedly from 7.0% to 51.3%, 0.1% to 5.9%, and 0.0% to 0.7%, respectively.

Figure 1

Conclusion

The incidence of AF in patients with PAD has significantly increased over time whereas a marked decline has occurred in the incidence of stroke. This suggests that the secondary prevention strategies aimed at reducing risk of stroke are broadly effective. Moreover, due to global aging, earlier and more frequent diagnosis, and improved treatment of cardiovascular risk factors may explain the increasing incidence of AF.
P937Impact of left ventricular diastolic dysfunction on long-term outcome in patients with lower extremity artery disease
Authors: Yanaka K , Akahori H , Imanaka T , Miki K , Yoshihara N , Tanaka T , Asakura M , Yanaka K
Published: October 2019

Background

Left ventricular (LV) systolic dysfunction and heart failure (HF) in patients with lower extremity artery disease (LEAD) is associated with an increased risk for adverse events. However, relationship between long-term outcome in patient with LEAD and LV diastolic dysfunction remains unclear.

Purpose

The aim of this study was to assess the impact of LV diastolic dysfunction on long-term outcome in patients with LEAD.

Methods

Two hundred patients (male 66%, mean age 76±9 years) with preserved LV systolic function assessed by echocardiography (ejection fraction ≥50%) were enrolled from a single-center database between January 2013 to May 2015. Baseline LEAD was identified by ABI <0.9 or history of lower extremity revascularization. Diagnosis of LV diastolic dysfunction was based on the ASE/EACVI guidelines. The 3-year cumulative incidence of primary endpoint compared between LEAD patients with LV diastolic dysfunction than those without. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke and hospitalization for HF during 3 years follow-up. Multivariate analysis was performed to determine whether LV diastolic dysfunction was independently associated with the primary endpoint.

Results

LV diastolic dysfunction was identified in 31%. The mean observation period was 32±21 months. The primary endpoint occurred more frequently in patients with LV diastolic dysfunction than those without at 3 years (30% vs 16%, P=0.02). There were no significant differences between 2 groups in the myocardial infarction (3% vs 3%, P=0.73) and stroke (3% vs 3%, P=0.55). Cardiovascular death (19% vs 7%, P=0.01) and hospitalization for HF (19% vs 7%, P=0.01) were significantly higher in patients with LV diastolic dysfunction. In multivariate analysis, LV diastolic dysfunction was an independent predictor for primary endpoint (HR=2.28, 95% CI 1.10–4.73, P=0.02) (Table)

Predictor for primary endpoint Factors Univariate model Multivariate model Hazard ratio [95% CI] P value Hazard ratio [95% CI] P value Age 1.03 [0.98–1.08] 0.24 1.03 [0.98–1.08] 0.22 Chronic kidney disease 1.53 [0.77–3.07] 0.23 1.25 [0.60–2.58] 0.55 Coronary artery disease 1.08 [0.53–2.18] 0.84 1.18 [0.56–2.50] 0.65 Cerebrovascular disease 1.93 [0.74–5.02] 0.17 2.28 [0.86–6.05] 0.10 Critical limb ischemia 3.75 [1.68–8.37] <0.01 3.72 [0.56–2.50] <0.01 LV diastolic dysfunction 2.37 [1.18–4.74] 0.02 2.28 [1.10–4.73] 0.03

Conclusions

LV diastolic dysfunction increased the risk for adverse events in patients with LEAD.

Acknowledgement/Funding

None
P940Effects of IQOS smoking on vascular function, coronary flow reserve, myocardial deformation and myocardial work index during one month of use
Authors: Ikonomidis I , Katogiannis K , Kourea K , Kostelli G , Vlastos D , Varoudi M , Pavlidis G , Benas D , Trianatfyllou C , Karamichelakis N , Vrettou A R , Frogoudaki A , Thymis J , Triantafyllidi H , Iliodromitis E K
Published: October 2019

Background

IQOS smoking (heat-no burn smoke product) is proposed to reduce harm compared to conventional smoking. We examined its effects on vascular function, myocardial deformation and ventricular arterial coupling.

Methods

Thirty-seven current smokers (mean age 48±5 years, >20 cigarettes /day) without cardiovascular disease and 20 healthy subjects with similar age sex and risk factors participated in the study. All subjects were instructed to smoke only IQOS for one month. Measurements were performed at baseline and 1 month after smoking IQOS. we measured a) the aortic PWV (PWV) and central aortic systole blood pressure (SBPc) by Complior; b) the exhaled CO level (parts per million-ppm) as a smoking status marker; and c) brachial systolic (SBP)and diastolic (DBP) blood pressure and heart rate (HR) a) flow mediated dilation (FMD) of the brachial artery b) coronary flow reserve (CFR) after adenosine infusion by Doppler echocardiography and c) global longitundinal strain (GLS) peak twisting and untwisting velocity and myocardial work index derived by pressure –myocardial strain loops by speckle tracking imaging PWV to GLS ratio was also used as a marker of ventricular arterial coupling

Results

At baseline exhaled CO, PWV, SBPc, FMD, PWV/GLS ratio, myocardial work index and peak untwisting velocity were higher and CFR was lower in smokers compared to controls (14.9±7 vs. 4.2±1 ppm, p<0.001, 8.7±1.4 vs 10.0±1.6 m/s, p<0.05; 118±16 vs 110±7 mmHg p<0.001, 6.9±2 vs 9.5±2% p<0.001, −0.61±0.21 vs. −0.45±0.11 m/sec%, p<0.001, 1926±284 vs 1826±300 mmHg% p=0.04, −122±36 vs −95±25 deg/sec, p=0.02, 2.5±0.9 vs. 3.1±0.8 p=0.001 respectively). In the chronic phase we observed a significant improvement of FMD, CFR, GLS, PWV/GLS, myocardial work index and peak untwisting velocity compared to baseline (12±2% vs. 6.9±2%, p=0.03; 3.2±0.6 vs. 2.5±0.9 p=0.001; −19.3±2.2% vs. −21.1±2.8%, p=0.001; −0.61±0.21 vs. −0.47±0.12 m/sec% p=0.03; 1926±284 vs 1830±343 mmHg% p=0.03, −122±36 vs −105±25 deg/sec, p=0.03, respectively) in parallel with reduction of the exhaled CO (14.9±7 vs. 6±4.9 ppm, p<0.001). HR remained unchanged throughout the study and there was a borderline reduction of central aortic systolic blood pressure (118±16 vs. 114±19 mmHg, p=0.048).

Conclusions

Replacement of conventional cigarettes with IQOS results in improved LV longitundinal myocardial deformation, LV untwisting and reduced LV myocardial work index possibly linked to the concomitant improvement of aortic elasticity, endothelial and coronary microcirculatory function and ventricular-arterial coupling within 1 month.
P944Comparing therapeutic gap in lipid-lowering management between high-risk cardiovascular patients after acute coronary syndrome, stroke and critical limb ischemia
Authors: Yan B P Y , Chan C K Y , Lai W H S , To O T L
Published: October 2019

Background

Guidelines recommend intensive low-density-lipoprotein cholesterol (LDL-C) lowering in high cardiovascular (CV) risk patients with acute coronary syndrome (ACS), stroke and critical limb ischemia (CLI).

Purpose

We evaluated LDL-C goal attainment and lipid-lowering treatment (LLT) in a Chinese population with ACS, stroke and CLI patients.

Methods

We retrospectively evaluated consecutive high CV risk patients discharged between 2013 and 2017 from 3 hospitals in Hong Kong. Lipid profile and LLT were compared among 3 patient groups: ACS, Stroke and CLI.

Results

Of 10,168 high-CV risk patients (mean age 70.6±13.7 years; 62.4% male), 64.0% were ACS, 33.6% stroke and 2.5% CLI. Between baseline and 12-month, mean LDL-C reduced from 2.7±1.1 to 2.0±0.8 mmol/L in ACS patients, 2.7±1.0 to 2.0±0.7 mmol/L in stroke patients and 2.5±1.0 to 2.2±0.9 mmol/L in CLI patients (p<0.01). Proportion of CLI patients (29.9%) who achieved target LDL-C <1.8mmol/L at month 12 was significantly lower than stroke (45.6%) and ACS (48.2%) patients (p<0.01). The mean residual distance to target LDL-C was greatest in CLI (0.8±0.8 mmol/L) compared to stroke (0.6±0.6 mmol/L) and ACS (0.7±0.7 mmol/L) patients (p<0.01). Use of statin therapy on discharge was highest in ACS (88.4%) compared to stroke (78.3%) and CLI (52.6%) patients (p<0.01). But use of high-potency statin (rosuvastatin ≥20mg, atorvastatin ≥40mg or simvastatin ≥80mg) on discharge was very low in stroke (3.0%) and CLI (2.0%) compared to ACS (21.4%, p<0.01) patients. At 12 months 28.8% ACS, 34.3% stroke and 51.4% CLI patients were on no LLT (p<0.01) and the use of high-potency statin did not change significantly (3.0% in stroke, p=0.99; and 1.2% in CLI, p=0.48). Despite the poor achievement in LDL-C target in CLI patients, the proportion of CLI patients switching to high-potency statin (0.8%) was significantly lower than stroke (1.3%) and ACS (5.2%) patients (p<0.01).

Conclusion

This study demonstrated significant therapeutic gaps in lipid-lowering management in high CV risk patients. In particular, CLI patients were less aggressively treated with LLT and hence larger proportion of patient not achieving LDL-C target compared to ACS and stroke patients.
P946Abnormal ankle brachial indices are associated with ischemic stroke: evidence from a large cohort study
Authors: Bhatt S , Tseng A S , Girardo M , Firth C , Fortuin D , Liedl D , Wennberg P , Shamoun F E
Published: October 2019

Background

Peripheral arterial disease is a marker of aggressive atherosclerosis. The ankle brachial index (ABI) is a simple and non-invasive tool to diagnose peripheral arterial disease (PAD). Patients with PAD are at increased risk for ischemic strokes and other cardiovascular diseases.

Purpose

To evaluate the association of abnormal ABI and poorly compressible vessels with ischemic stroke in a large patient cohort.

Methods

We analyzed lower extremity vascular studies of all patients with ABI measurements at a tertiary care hospital between January 1996 and August 2018. PAD is defined as ABI<1.0, and poorly or non-compressible (PC/NC) arteries as ABI>1.4 while ABI between 1.0–1.4 is normal. Association of these ABIs with new ischemic stroke events post ABI measurement were analyzed after adjusting for high risk confounders such as atrial fibrillation. Hazard ratios (HR) were calculated using multivariable Cox proportional regression with 95% confidence intervals.

Results

In total, 38,016 unique patients (mean age 66.1±14.8 years, female 42.3%) were included. Abnormal ABI was found to be more prevalent among elderly male patients compared to patients with normal ABI. In contrast to non-PAD patients, both PAD and PC/NC patients as defined by ABI had a statistically significant risk of ischemic stroke, with PAD conferring the greatest risk compared to PC/NC vessels. The data is summarized in Table 1.

Table 1 Unadjusted HR p-value Adjusted HR p-value PAD vs. No PAD 2.77 (2.62, 2.92) <0.001 2.10 (1.98, 2.22) <0.001 PC/NC vs. No PAD 2.11 (1.95, 2.28) <0.001 1.38 (1.26, 1.51) <0.001 PAD vs. PC/NC 1.37 (1.28, 1.46) <0.001 1.37 (1.28, 1.48) <0.001 Adjusted and unadjusted hazard ratios with p-values. HR adjusted for age, sex, atrial fibrillation, ischemic stroke, transient ischemic attack, chronic heart failure, diabetes mellitus, hyperlipidemia, hypertension, and coronary artery disease. PAD = Peripheral artery disease and PC/NC = poorly compressible/non-compressible.

Conclusion

This study adds to the growing body of evidence that PAD and poorly-compressible vessels are independently associated with an increased risk of ischemic stroke. Given the associated risk of cerebrovascular disease, clinicians should aggressively treat to minimize risk factors in those with abnormal ABIs.
P947Combining the ankle-brachial index with novel waveshape-based methods improves peripheral artery disease classification
Authors: Bachler M , Haumer M , Hametner B , Mayer C C , Glantschnig K , Wassertheurer S
Published: October 2019

The Ankle Brachial Index (ABI) is the most commonly used method for the investigation of peripheral artery disease (PAD) in clinical settings, but has a low sensitivity for detecting PAD in asymptomatic patients. It is calculated only based on the systolic blood pressure in the limbs and ignores the shape of the pressure waves. Therefore, we investigated a novel method focusing on waveform changes by analyzing and comparing synchronous pulse wave recordings of all four extremities.

In this study, pulse waves of 44 patients (28M/16F, age 65 (SD 10) years, ABI 0.89 (SD 0.13)) measured at rest on all four limbs simultaneously using the AngE Pro 4 system (Sonotechnik Austria Angio Experience GmbH, Austria) were investigated. The patients Fontaine stage was used as a benchmark. A novel parameter based on pairwise wave shape differences, i.e., the root mean square of the differences (RMSD), was tested for its capability to correctly classify the patients Fontaine stage. Furthermore, the results were compared and combined with ABI measurements.

Of the 44 patients, 7 were in Fontaine stage 0 (no PAD) and 37 in stage 2 (claudication). In univariate analysis, ABI showed significant discrimination power (AUC ROC = 0.86, p<0.01), but was surpassed by the RMSD with a discrimination power beyond ABI (AUC ROC = 0.95, p<0.001, see figure). Furthermore, logistic regression revealed statistical independence of ABI and RMSD, indicating that they reflect different aspects of the measurements. Therefore, combining these two measures, multivariate classification results in a far superior classifier (AUC ROC = 0.98, p<0.001, see figure).

In this study, the novel waveshape-based method RMSD, used to classify stages of PAD, showed better discrimination power than ABI. Furthermore, statistical independence allowed for the combination of ABI and RMSD, resulting in a far superior classification of PAD Fontaine stages. Since, using the appropriate equipment, both parameters can be measured simultaneously and in an automated way, the results are promising for assisting PAD classification in the future.

Acknowledgement/Funding

This work was partly supported by the program “Bridge” by the Austrian Ministry for Transport, Innovation and Technology BMVIT. PWA4PAD FFG No. 858509
P949Early QW duration, depth and area in prediction of reperfusion success in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention - a CMR study
Authors: Topal D
Published: October 2019

Background

Pathological Q-wave (QW) in the electrocardiogram (ECG) before primary percutaneous coronary intervention (primary PCI) is a strong prognostic marker in patients with ST-segment elevation myocardial infarction (STEMI). However, current QW criteria are either not clinical applicable or have a lack of diagnostic performance. Furthermore, the term “pathological” QW is debatable given that even patients with large pathological QW do have substantial myocardial salvage index. Accordingly, we evaluated the association between QW duration, depth, area (QW morphology) and non-viable myocardium, myocardial salvage index as well as microvascular obstruction (myocardial salvage index and microvascular obstruction are considered reperfusion success) using cardiac magnetic resonance imaging (CMR).

Methods

A total of 516 patients with their first STEMI had obtained an ECG before primary PCI and an additional CMR performed acute at day 1 (interquartile range [IQR], 1–1) and at follow-up at day 92 (IQR, 89–96). The largest measurable QW in ECG was used for analysis of QW morphology. A new QW criteria (Copenhagen QW criteria) composite of duration and depth as well as a new QW area criteria were made using ROC-analysis, and were compared with modified Minnesota criteria.

Results

The QW morphology was strongly associated to all CMR endpoints (p≤0.0001) and showed a strong linear correlation with final infarct size, final transmurality and final myocardial salvage index (p≤0.0001). The diagnostic performance of QW morphology, Copenhagen QW criteria and QW area criteria was over-all comparable to the modified Minnesota criteria in prediction of non-viable myocardium.

Conclusion

QW morphology in STEMI patients has a strong linear association with reperfusion success. The larger final infarct size, final transmurality or lower final myocardial salvage index the larger QW morphology. Hence, it is suggested that the term pathological is not used as a dichotomous condition in patients with STEMI but rather evaluated on the basis of extent.

Acknowledgement/Funding

Rigshospital Research Fund
P952Choosing an effective methods for assessing the results of percutaneous coronary interventions in post-myocardial infarction patients
Authors: Rustamova Y , Azizov V , Dzhahangirov T , Imanov G , Maximkin D A , Faibushevich A
Published: October 2019

Aim

To evaluate the effectiveness of cardiac magnetic resonance (CMR) and stress-echocardiography in the assessment of long-term results of percutaneous coronary interventions (PCI) in post-MI patients with dysfunctional myocardium.

Methods

112 patients were participated in the study. Inclusion criteria: myocardial infarction in previously; angina II-III functional class (CCS); multivessel coronary disease (SYNTAXscore I <32); the presence of segments with abnormality left ventricular local contractility; chronic heart failure I-III functional class (NYHA); left ventricular ejection fraction (LVEF) is less than 45%. All patients underwent stenting of the coronary arteries in the zone of viable myocardium. Only drug-eluting stents were implanted in coronary arteries. Long-term results were followed up 18 months after PCI in all patients. All patients underwent stress-echocardiography and CMR for visualization of myocardium after PCI.

Results

On average, initially accounted for 2.12±0.74 segments with abnormality kinetic per patient according CMR, whereas, according to stress echocardiography, the average number of segments was 1.96±0.42. The average difference was 0.16 segment [0.11–0.18; 95% CI, p=0.003]. In the postoperative period, after 18 months, there was a significant decrease a segments with abnormality kinetics in the zone of hibernated myocardium, from 2.12 to 1.08, according to CMR (the average difference was 1.04 segment) [0.98–1.1; 95% CI, p<0.01], and from 1.96 to 0.98 according to stress-echocardiography (the average difference was 0.98 segments) [0.94–0.99; 95% CI, p=0.023]. There is a significant discrepancy between the number of identified segments with abnormality kinetics using CMR and stress- echocardiography. There was a significant decrease in the transmurality index from 0.42 to 0.31 (according to CMR). The difference was 0.11 [0.09–0.14; 95% CI, p<0.05]. At the same time, recovery of myocardial function was clearly manifested in patients with a trasmurality index of 0.3–0.5, whereas with a transmurality index of more than 0.5, reliable recovery of myocardial function was not observed.

Conclusion

CMR allows a more objective analysis of the results of PCI in patients with dysfunctional myocardium, as compared with the stress-echocardiography method.

Acknowledgement/Funding

Russian Academic Excellence Project 5-100
P953Comparison of the original and updated ACTION risk scores for predicting in-hospital and one-year mortality in patients with acute myocardial infarction undergoing primary PCI
Authors: Jelic D , Mehmedbegovic Z , Milasinovic D , Dedovic V , Zobenica V , Zaharijev S , Radomirovic M , Asanin M , Vukcevic V , Stankovic G
Published: October 2019

Background

The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With The Guidelines (GWTG) AMI mortality model and risk score (ACTION) were introduced in 2011 to predict in-hospital mortality. In 2016 score was updated to enable a more accurate assessment, but, up-to-date, external validation in direct comparison was not performed.

Purpose

We aimed to externally validate and compare the prognostic value of original and updated ACTION score for in-hospital and one-year mortality.

Method

From a prospective electronic registry of a high-volume catheterization laboratory in a period from January 2009 to December 2017, a total of 5615 consecutive patients who underwent pPCI were available for analysis. For each patient, original (O-) and updated (U-) ACTION scores were calculated using required clinical and angiographic characteristics. In-hospital and one-year mortality (follow-up available for 91%) were assessed. Calibration and discrimination of the three risk models were evaluated by the Hosmer-Lemeshow (H-L) goodness-of-fit test and C-statistic, respectively.

Results

Mortality rates for in-hospital and one-year mortality were 4.2% and 9.6%, respectively. Both scores showed good model calibration as assessed by the H-L test and very good discriminative power for in-hospital and one-year mortality as assessed by C-statistics (Table 1 & Figure 1).

Net reclassification index (NRI=1.06) showed that 48% of patients with in-hospital event and 58% without event, had their risk recalculated with U-ACTION with Integrated Discrimination Improvement slope 9.1% higher than in first model.

Table 1 Risk score H-L H-L p value AUC 95% CI p value AUC 95% CI Significant p value O-ACTION 9.4 0.3 0.829 0.819 to 0.839 p<0.0001 0.781 0.769 to 0.792 p<0.0001 U-ACTION 10.9 0.2 0.918 0.911 to 0.925 0.838 0.827 to 0.848

Figure 1

Conclusion

Updated ACTION score enables better prediction of in-hospital and one-year mortality in patients undergoing pPCI for acute myocardial infarction, thus it can be used preferentially over the original ACTION score for assessment of short and long-term mortality risks of this population.
P962Follow-up of protected high-risk percutaneous coronary intervention with microaxial Impella pump. Results from the retrospective German Impella Registry
Authors: Baumann S , Werner N , Al-Rashid F , Schaefer A , Bauer T , Sotoudeh R , Bojara W , Shamekhi J , Sinning J.-M , Becher T , Eder F , Akin I
Published: October 2019

Background

Percutaneous coronary intervention (PCI) presents a relevant alternative to coronary bypass surgery for the treatment of patients with complex coronary artery disease and high perioperative risk. By temporary implantation of a percutaneous ventricular assist devices (pVAD) interventionalists attempt to anticipate the hemodynamic risk of those high-risk patients in a so-called protected PCI. The Impella® system presents the currently most common device for protected PCI and could show hemodynamic stability in earlier trials.

Methods

This study is a retrospective, observational multi-center registry of ten hospitals in Germany. We included patients undergoing protected high-risk PCI with Impella® support. The primary endpoint was defined as major adverse cardiac events (MACE) during a 180-day follow-up and consisted of all-cause mortality, myocardial infarction (MI) and stroke.

Results

Six of the participating hospitals performed a follow-up. In total, 157 patients (80.3% male; mean age 71.8±10.8 years) were included in the present study. Prior to PCI, median left ventricular ejection fraction was 39.0% (25.0%-50.0%) and median SYNTAX-Score I was 33.0 (24.0–40.5). The 180-day follow-up was available for 149 patients (94.9%). Eight patients (5.1%) were lost to follow-up. During the follow-up period, 34 patients (22.8%) suffered from a MACE. A total of 27 patients (18.1%) died. Nine patients (6.0%) sustained a MI, while 4 patients (2.7%) had a stroke.

Kaplan-Meier curves for primary endpoint

Conclusions

Patients undergoing protected high-risk PCI with Impella® support show a good 180-day clinical outcome regarding rates of MACE and mortality. However, a head-to-head comparison of Impella supported patients to protected PCI with other pVADs is pending.

Acknowledgement/Funding

S.B., N.W., F.A.-R., J.-M.S., A.S., R.S., I.A. receive consulting fees/honoraria from Abiomed (Danvers, MA, USA).
P965Prevalence, management strategies and outcomes of patients with coronary chronic total occlusions
Authors: Guo L , Wu J , Zhong L , Huang R C
Published: October 2019

Background

Percutaneous coronary intervention (PCI) for coronary chronic total occlusions (CTOs) remains among the biggest challenges in interventional cardiology. However, limited data exist regarding the clinical outcomes of the three potential therapeutic strategies of PCI, coronary artery bypass grafting (CABG), and medical therapy (MT).

Aims

The aim of this study was to compare the clinical outcomes of CTO patients according to the initial treatment strategy.

Methods and results

Consecutive patients with at least one coronary CTO from January 2007 to December 2016 in our center were included and categorized as managed either by PCI, CABG, or MT. Propensity-score matching was also performed to adjust for baseline characteristics. The primary outcome was a major adverse cardiac event (MACE), such as cardiac death, myocardial infarction (MI), or target vessel revascularization (TVR). A total of 1655 patients with 1944 CTOs were enrolled in this study. The overall CTO prevalence was 10.5%. A CTO was treated by MT in 800 (48.3%) patients and PCI in 734 (44.4%), while 121 (7.3%) underwent CABG. The median overall follow-up duration was 3.6 (interquartile range = 2.1 to 5.0) years. Patients referred for MT had a higher incidence of MACE (28.0% vs. 17.3% and 12.4%, respectively; all p<0.001) and TVR (16.9% vs. 10.6% and vs. 7.4%, respectively; p<0.001 and = 0.005, respectively) than those managed by PCI and CABG. After propensity-score matching analysis, the rate of PCI was lower than that of MACE (19.2% vs. 28.9%, hazard ratio [HR] = 0.62, 95% confidence interval [CI] = 0.45–0.85, p=0.003) and TVR (HR = 0.53, 95% CI = 0.35–0.79, p=0.002) when compared with MT. There was no significant difference in the prevalence of MACE (18.5% vs. 23.1%, HR = 0.76, 95% CI = 0.53–1.09, p=0.126) or cardiac death (0.51; 0.23–1.15, 0.098) between the successful PCI and MT groups.

Conclusions

As an initial management strategy for patients with CTOs, PCI or CABG reduced the risk of MACE (driven by TVR), as compared with MT alone on follow-up. However, successful PCI did not reduce the long-term risk of MACE or cardiac death, as compared with MT alone.

Acknowledgement/Funding

Beijing Municipal Science and Technology Project (Z1611ehz747.05590516139) and BeijingLisheng Cardiovascular Health Foundation (LHJJ20158521)
P967Combined modified balloons and Saito's modified JBT for calcified coronary birucation lesions
Authors: He J , Wang L F , Yang X C
Published: October 2019

Background

Bifurcation lesions are account for relatively high incidence of adverse events, especially in serious calcification and distort lesions during bifurcation stenting.

Purpose

Based on Saito's modified jailed balloon technique (M-JBT, Shigeru Saito, Modified jailed balloon technique for bifurcation lesions, Catheter Cardiovasc Interv. 2018; 92:E218–E226), fully dilatation with modified balloons was performed on calcification lesion in main branch, to observe if this combination method will facilitate bifurcation lesions stenting procedure.

Methods

For M-JBT, we followed Saito's technique. Basically, a jailed balloon (JB) is introduced into the side branch (SB), while a stent is placed in the main branch (MB) as crossing SB. The size of the JB is half of the MB stent size. While the proximal end of JB attaching to MB stent, both stent and JB are simultaneously inflated with same pressure. Kissing balloon dilatation (KBD) and/or T and protrusion (TAP) stenting are applied as needed.

Modified balloons are performed as severe calcification presented in MB.

Results

More than 50 patients and 60 bifurcations (both for selective and primary cases) underwent percutaneous coronary intervention (PCI) using this combined technique since November 2018. Procedure success was achieved in all cases. KBD was performed for a few lesions and TAP stenting was employed for 1 lesion. Occlusion of SV was not observed in any of the patients.

Illustration cases and prodedure

Conclusions

Saito's modified jailed balloon technique is safe and effective method in bifurcation stenting. Combined with modified balloons is an effective method when severe calcification presented in bifurcation lesions, especially in distort lesion (main branch or side branch) and poor position visualization situations when rewire is difficult in traditional JBT procedure.

Acknowledgement/Funding

None
P979Persistent atrial fibrillation terminated within the left atrium without recurrence at follow-up demonstrates a gradual intracardiac organization during stepwise ablation
Authors: Pithon A , Luca A , Buttu A , Vesin J M , Roten L , Kuhne M , Spiess F , Knecht S , Sticherling C , Park C I , Pascale P , Le Bloa M , Herrera C , Pruvot E
Published: October 2019

Introduction

We previously reported that patients (pts) with recurrence (Rec) after stepwise catheter ablation (step-CA) of persistent atrial fibrillation (pAF) exhibit high bi-atrial intracardiac dominant frequencies (DF) values before ablation, indicative of a severe bi-atrial electro-anatomical remodeling.

Purpose

Herein, we hypothesized that a gradual decrease in DF values during step-CA is associated with pAF termination and maintenance of sinus rhythm (SR) on the long term.

Method

In 40 consecutive pts (61±8 yo, sustained AF duration 19±11 months), pulmonary vein isolation (PVI) and left atrium (LA) ablation were performed until pAF termination or cardioversion. 10-sec intracardiac electrograms (EGMs) epochs were recorded before ablation (BL), during PVI and during complex fractionated atrial electrograms (CFAEs) and linear ablation (post_PVI) in the right atrial (RAA) and left atrial (LAA) appendages and in the coronary sinus (CS). DF was defined as the highest peak within the [3–15] Hz EGM spectrum. Rec was defined as any atrial arrhythmia lasting >30 sec during follow-up (FU).

Results

pAF was terminated within the LA in 70% (28/40, LT) of the pts, while 30% (12/40, NLT) were not. After a mean FU of 34±14 months, all NLT pts had a Rec, while LT pts presented a Rec in 71% (20/28, LT_rec) and remained in SR in 29% (8/28, LT_norec). Figure 1 shows: 1) a gradient in DF values measured in the LAA (panel A), RAA (panel B) and CS (panel C) with the highest values in NLT pts (red), intermediate values in LT_rec pts (yellow) and lowest DF values in LT_norec pts (green); 2) all three groups displayed a gradual intracardiac organization during LA ablation as shown by decreasing DF values (p<0.05, BL vs post_PVI), but the LT_norec pts (green) exhibited the highest relative changes in DF from BL (p<0.05, LT_norec vs NLT, Δ range: −5.31 to −9.69%).

Figure 1. Effect of ablation on DF

Conclusion

Low DF values before ablation and gradual intracardiac organization until pAF termination are associated with maintenance of SR on the long term.
P985The long-term impact of maintaining sinus rhythm on the risk for death or heart failure after catheter ablation for atrial fibrillation in a real world clinical practice
Authors: Yoshizawa T , Shiomi H , Tanaka M , Aizawa T , Yamagami S , Komasa A , Kimura T , Shizuta S
Published: October 2019

Background

Catheter ablation has been rapidly spread as a first line therapy for atrial fibrillation (AF). A recent randomized trial have shown that AF ablation reduces the risk of death or hospitalization for heart failure (HF). However, the impact of maintained sinus rhythm (SR) on long-term risk of death or HF hospitalization has not been adequately evaluated.

Purpose

To investigate the impact of maintaining SR by AF ablation on long-term risk of all-cause death or HF hospitalization.

Methods

The long-term clinical outcomes were compared between patients with maintained SR and those with recurrent AF using a landmark analysis in which the landmark point was set at 1.5-year after the 1st ablation.

Results

Among consecutive 1467 patients who underwent AF ablation in our institution between February 2004 and December 2017, the study population consisted of 1311 patients after excluding 150 patients because of death or lost to follow-up. Mean age was 67.9±0.3 and paroxysmal AF was 67%. Among 460 patients who had AF recurrence within 1.5 years after the 1st ablation, 328 underwent 2nd ablation. Therefore, at 1.5-year after the 1st AF ablation, 1145 patients had maintained SR rhythm (SR-group), and 166 patients had recurrent AF episodes (AF-group). During 4.7±2.4 years of follow-up, the cumulative 5-year incidence of death or HF beyond 1.5 years after the 1st ablation was 5.1% in SR-group and 15.6% in AF-group (log rank P<0.001). After adjusting for baseline confounders, the lower risk of SR-group relative to AF-group for death or HF was still statistically significant (HR: 2.05, 95% CI: 1.11–3.58, P=0.02).

Risks for a Composite of Death or HF Hazard Ratio (95% CI) Crude HR P value Adjusted HR P value AF recurrence 2.59 (1.43–4.43) 0.002 2.05 (1.11–3.58) 0.02 Age>75 years old 2.55 (1.56–4.10) <0.001 2.32 (1.39–3.81) 0.002 Female 0.85 (0.49–1.43) 0.56 0.73 (0.40–1.25) 0.26 PeAF 1.25 (0.68–2.16) 0.45 0.98 (0.52–1.75) 0.94 LSAF 1.10 (0.46–2.23) 0.82 0.70 (0.28–1.53) 0.39 LVEF>50% 0.27 (0.16–0.48) <0.001 0.57 (0.31–1.09) 0.09 Past history of HF 7.06 (4.18–11.6) <0.001 4.67 (2.51–8.41) <0.001 CKD 4.74 (2.08–9.39) <0.001 2.23 (0.94–4.69) 0.07 AF, Atrial fibrillation; PeAF, Persistent AF; LSAF; Long standing AF; HF, Heart failure; CKD, Chronic kidney disease.

Figure 1

Conclusions

Successfully maintained SR was associated with reduced long-term risk for death or HF hospitalization in real world patients undergoing AF ablation.
P986Future risk of bradyarrhythmias in patients with hypertrophic cardiomyopathy and implantable cardioverter defibrillator indication
Authors: Nakasuka K , Kitada S , Kawada Y , Kato M , Ohte N
Published: October 2019

Background

Subcutaneous-implantable cardioverter defibrillator (S-ICD) has been shown to be effective for prevention of sudden cardiac death. Patients with hypertrophic cardiomyopathy (HCM) having ICD indication are considered to introduce either S-ICD or transvenous-ICD, however it is uncertain which is better since S-ICD is not suitable for patients who need pacing and data on the necessity for pacing in HCM patients are limited.

Purpose

The purpose of this study was to investigate the risk factors associated with the future risk of bradyarrhythmias needed to be paced in patients with HCM and ICD indication.

Methods

This is a retrospective, single-center cohort study. Of 169 HCM patients diagnosed in our institution, 80 with ICD indication in accordance with the Japanese guideline in 2011 were enrolled as study subjects (31 females, mean age 63±15 years). They were divided into two groups – patients who progressed to bradyarrhythmias which needed pacing during the follow-up period (Brady group) and those who not (Non-brady group). Baseline characteristics at the time of diagnosis of HCM including demographic information, the results of clinical examination such as blood test, echocardiography and electrocardiography (ECG) were compared between the Brady and Non-brady group.

Results

During a mean follow-up period of 6.8±5.4 years, 9 patients (11%) progressed bradyarrhtyhmias which needed pacing. Symptomatic sick sinus syndrome (SSS) was the primary cause (7 SSS, 1 atrial fibrillation [AF] with bradycardia, 1 after atrioventricular nodal ablation). Comparing between the Brady and Non-brady group, there was no significant difference in clinical variables such as age, heart rate, PR interval and QRS duration in ECG, EF levels, BNP levels, beta-blocker usage rate, prevalence of hypertension or diabetes mellitus. On the other hand, women were more in Brady group than in Non-brady group (7/9, 78% vs. 24/71, 34%; p=0.01). Furthermore, more patients in Brady group had documented AF at the beginning and during follow-up period (7/9, 78% vs. 25/71, 36%; p=0.02) and took anti-arrhythmic drugs (AAD) (8/9, 89% vs. 19/71, 27%; p<0.001) including amiodarone than those in Non-brady group.

Conclusion

In HCM patients with ICD indication, around 10% of patients have a potential risk of bradyarrhythmias needed to be paced, especially in female, those with AF and/or AAD usage.
P1011Electrophysiological trends in Wolff-Parkinson-White patients: a 33 years follow-up study
Authors: Fioravanti F , Fenici R , Sorbo A R , Brisinda D
Published: October 2019

Background

The Wolff-Parkinson-White (WPW) syndrome can be associated with sudden cardiac death, therefore risk assessment (RA) with electrophysiological (EP) testing (EPT) is mandatory to identify patients (pts) requiring catheter ablation (CAb). Our retrospective cohort study aimed to evaluate the variability of EP parameters during follow-up of WPW pts and the reliability of trans-esophageal EPT (TEEPT) for RA, evaluation of treatment efficacy, and EP follow-up of untreated athletes/pts.

Method

Data of 335 WPW pts, studied with TEEPT between 1985 and 2018, were retrospectively analyzed. Anterograde effective refractory period (ERP) of accessory pathways (AP) and of the atrioventricular node, Wenckebach point, shortest preexcited RR intervals (SPERRI) during atrial fibrillation (AF) and/or atrial pacing (At-P) and inducibility of supraventricular arrhythmias were assessed, at rest (supine and standing) and during effort. An AP was defined at high arrhythmogenic risk (HAR) if the anterograde AP-ERP and/or SPERRI (in AF or At-P) were ≤240 ms at rest or ≤200 ms during effort test. All patients were followed-up as outpatients or telephonically, as clinically required.

195 pts (17% female) were included, having exhaustive clinical information, two or more TEEPT and exhaustive clinical follow-up until late 2018. Time-evolution of EP parameters was evaluated, using parametric and non-parametric tests, as appropriate.

Results and discussion

Median age at first TEEPT was 20 years (IQR 16–29 years). Median follow- up was 44.3 months (IQR 16.4–122.9 months). Two pts (both identified at HAR and scheduled for surgery when ablation was unavailable) died suddenly, at rest. No other serious arrhythmic complication occurred, during the FU. Out of 19 pts (9.7% - Group A) showing enhanced AP conductivity at follow-up (mean ERP/SPERRI shortening: 30.8 ms, range 10–80 ms), 4 pts were found at HAR and underwent CAb.

176 pts (90.3% – Group B) showed a stable or impaired (25% under pharmacological treatment) AP conductivity during the follow-up. Their mean ERP/SPERRI increase was 39.7 ms (range 0–130 ms). Group A pts were significantly younger (20 vs 28 years old; 88% of Group A pts were <30 years old) and more frequently male (94.1% vs 80.6%). A non-significant trend toward Group A was found for antero-septal APs (35% Group A vs 15.4% Group B).

Conclusions

TEEPT is a safe, non-invasive tool to stratify arrhythmogenic risk of WPW pts. Our data suggest that a watchful waiting is safe for low to moderate risk pts. Younger males with an antero-septal Kent bundle may deserve a more intensive EP follow-up. Aggressive therapy should be considered as mandatory only for symptomatic HAR pts, taking into account complications, risk/benefit ratio and pts' preferences. In other cases, medical therapy and watchful observation could be applied safely under periodical TEEPT, as appropriate.
P1012Radiofrequency catheter ablation of accessory pathways at the site of prior valve surgery
Authors: Uhm J S , Kim J , Jin M N , Kim I S , Bae H J , Cho M S , Yu H T , Kim T H , Joung B , Pak H N , Nam G B , Choi K J , Kim Y H , Lee M H
Published: October 2019

Background

Radiofrequency catheter ablation (RFCA) for accessory pathways (APs) at the site of prior valve surgery remains challenging. We aimed to clarify the factors associated with successful RFCA for such APs.

Methods

Upon reviewing a RFCA registry and previous case reports, we included nine patients who underwent RFCA of APs at the site of prior valve surgery (total-VS group; age, 34.0 [24.5–45.0] years; men, 4/9) and 196 patients who underwent RFCA of APs with no history of valve surgery (no-VS group; age, 40.5 [23.0–54.0] years; men, 114/196). Electrophysiological features, procedural details, and outcomes were examined.

Results

AP exhibited decremental conduction in four of nine patients in the total-VS group. The number of RFCA attempts was significantly higher in the total-VS group than in the no-VS group (10.0 [4.5–14.5] vs 2.0 [1.0–3.0]; p<0.001). In four patients who underwent mitral valve surgery, successful RFCA was achieved using the transaortic approach, coronary sinus approach, or bipolar ablation. In three patients who underwent tricuspid valve surgery, successful RFCA was achieved using the above-prosthetics or trans-prosthetics approach. In two patients, RFCA failed. The trans-prosthetics approach and bipolar ablation technique were effective. The transaortic and coronary sinus approaches were occasionally effective. The transseptal approach was ineffective. Based on the success rate and accessibility, we suggest a stepwise approach to RFCA of APs at the site of prior mitral or tricuspid valve surgery (Figure).

Stepwise approach to AP at valve surgery

Conclusions

Successful RFCA of APs at the site of prior valve surgery can be achieved by detailed mapping of the areas both above and below the prosthetic valve, as well as by ensuring effective radiofrequency energy delivery using various catheter approaches and RFCA techniques.